The hybridoma methodology for developing monoclonal antibodies has been a lab staple for more than 30 years, and it still works great for immunohistochemistry and various cell biology techniques. During the past decade, however, recombinant technologies for antibody development, combinatorial libraries, and antibody engineering have gained a strong following, especially for high-end antibody applications, including therapeutic drug development.
Survey Series
For Advertisers
Antibodies Go Recombinant
Tips and resources for choosing the right antibody development program.
(continued >>)
To continue reading this full article, you must be a subscriber to The Scientist.
You are only a few minutes away from unlimited access.
If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
Subscribe to The Scientist to get unlimited access to our premium content
Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95. Subscribe now.The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.